Lynette Kiers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lynette Kiers has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Belinda Cruse
Department of Neurology Royal Melbourne Hospital Parkville VIC Australia
2 shared publications - Antonino Uncini
Department of Oncology and Neurosciences, “G. d’Annunzio” University and the Aging Research Center, Ce.SI, “G. d’Annunzio” University Foundation, Chieti-Pescara, Italy
1 shared publication - Badrul Islam
Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication Bart C Jacobs
Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
1 shared publication- Beth Stein
Department of Neurology, St. Joseph's Regional Medical Center, Paterson, USA
1 shared publication - Camiel Verhamme
Department of Neurology Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Neurology Open
- Vol. 7 (2) , e001318
Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory, immune-mediated neuropathy of the peripheral nerves and nerve roots. CIDP is unlikely to be a discrete disease entity, but rather a spectrum of related conditions, in which cell-mediated and humoral mechanisms act synergistically to cause damage to peripheral nerves. The 2021 guideline of the European Academy of Neurology/Peripheral Nerve Society on the diagnosis and treatment of CIDP has modified the CIDP spectrum to include typical CIDP and four well-defined CIDP variants. Patients with CIDP usually respond well to immunoglobulin therapy, steroids or plasmapheresis; however, 20–30% do not respond well, and approximately 15% remain refractory to all treatment modalities. Rituximab, mycophenolate mofetil and cyclophosphamide are of therapeutic benefit for some of these patients. Patients with some CIDP variants respond less well to immunotherapy, suggesting a difference in the pathogenic mechanisms underlying these variants. Potential novel treatments trialled in CIDP, targeting functionally relevant disease mechanisms, include neonatal Fc receptor blockers and complement inhibitors. These new treatment approaches are needed to optimise disease outcomes in refractory patients, and as an alternative for patients with suboptimal response requiring high doses or experiencing side effects from first-line therapies. Increasing the therapeutic options for patients with CIDP, particularly for refractory patients, highlights the need for more accurate diagnosis of typical CIDP and CIDP variants, objective evidence of treatment response and the need for reliable clinical biomarkers.
- 1 July 2025
- Published by BMJ in BMJ Neurology Open
- Vol. 7 (2) , e001318
Open AccessEvaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory, immune-mediated neuropathy of the peripheral nerves and nerve roots. CIDP is unlikely to be a discrete disease entity, but rather a spectrum of related conditions, in which cell-mediated and humoral mechanisms act synergistically to cause damage to peripheral nerves. The 2021 guideline of the European Academy of Neurology/Peripheral Nerve Society on the diagnosis and treatment of CIDP has modified the CIDP spectrum to include typical CIDP and four well-defined CIDP variants. Patients with CIDP usually respond well to immunoglobulin therapy, steroids or plasmapheresis; however, 20–30% do not respond well, and approximately 15% remain refractory to all treatment modalities. Rituximab, mycophenolate mofetil and cyclophosphamide are of therapeutic benefit for some of these patients. Patients with some CIDP variants respond less well to immunotherapy, suggesting a difference in the pathogenic mechanisms underlying these variants. Potential novel treatments trialled in CIDP, targeting functionally relevant disease mechanisms, include neonatal Fc receptor blockers and complement inhibitors. These new treatment approaches are needed to optimise disease outcomes in refractory patients, and as an alternative for patients with suboptimal response requiring high doses or experiencing side effects from first-line therapies. Increasing the therapeutic options for patients with CIDP, particularly for refractory patients, highlights the need for more accurate diagnosis of typical CIDP and CIDP variants, objective evidence of treatment response and the need for reliable clinical biomarkers.
- Open Access
- 13 January 2022
- Published by Elsevier in Clinical Neurophysiology
- Vol. 138, 231-240
Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values
- 13 January 2022
- Published by Elsevier in Clinical Neurophysiology
- Vol. 138, 231-240
Open AccessElectrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values
- 27 September 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 52 (5) , 740-744
Nitrous oxide‐induced neurological disorders: an increasing public health concern
Background: Neurological presentations resulting from nitrous oxide (N2O) abuse are increasing in Australia and worldwide. Despite known neuropsychiatric sequelae, N2O canisters remain readily available and its use unregulated.Aims: To examine the demographics, clinical and electrophysiological findings of patients presenting with neurological complications of N2O abuse, and thus inform clinicians and public health decision‐makers of the significant public health concerns of this increasing practice.Methods: Consecutive patients presenting to a tertiary referral metropolitan hospital were included in this series. Patients were identified by a search of discharge summaries of patients admitted with acute or subacute neuropathy or myelopathy and a history of N2O abuse, and from the electrophysiology database.Results: Thirteen patients were identified, most presenting with subacute paraesthesia, sensory ataxia and lower limb weakness. Eleven had low serum vitamin B12. Spinal magnetic resonance imaging was consistent with subacute combined degeneration in eight. Nerve conduction studies revealed a motor or sensorimotor axonal neuropathy (three with motor predominance). There was a bimodal demographic distribution consisting of socially isolated, international university students and local residents with a history of mental illness and polydrug abuse.Conclusions: Recreational N2O use is an emerging health problem in Australia. International university students and patients with pre‐existing mental illness or polydrug use appear to be at increased risk. A severe motor neuropathy may emerge following vitamin B12 replacement. Public health measures are required to limit the availability of N2O and to educate adolescents and young adults about the potential for significant harm.
- 27 September 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 52 (5) , 740-744
Nitrous oxide‐induced neurological disorders: an increasing public health concern
Background: Neurological presentations resulting from nitrous oxide (N2O) abuse are increasing in Australia and worldwide. Despite known neuropsychiatric sequelae, N2O canisters remain readily available and its use unregulated.Aims: To examine the demographics, clinical and electrophysiological findings of patients presenting with neurological complications of N2O abuse, and thus inform clinicians and public health decision‐makers of the significant public health concerns of this increasing practice.Methods: Consecutive patients presenting to a tertiary referral metropolitan hospital were included in this series. Patients were identified by a search of discharge summaries of patients admitted with acute or subacute neuropathy or myelopathy and a history of N2O abuse, and from the electrophysiology database.Results: Thirteen patients were identified, most presenting with subacute paraesthesia, sensory ataxia and lower limb weakness. Eleven had low serum vitamin B12. Spinal magnetic resonance imaging was consistent with subacute combined degeneration in eight. Nerve conduction studies revealed a motor or sensorimotor axonal neuropathy (three with motor predominance). There was a bimodal demographic distribution consisting of socially isolated, international university students and local residents with a history of mental illness and polydrug abuse.Conclusions: Recreational N2O use is an emerging health problem in Australia. International university students and patients with pre‐existing mental illness or polydrug use appear to be at increased risk. A severe motor neuropathy may emerge following vitamin B12 replacement. Public health measures are required to limit the availability of N2O and to educate adolescents and young adults about the potential for significant harm.
- 24 April 2015
- Published by Wiley in Muscle & Nerve
- Vol. 51 (6) , 928-931
Distal acquired demyelinating symmetric (DADS) neuropathy associated with colorectal adenocarcinoma
Introduction: Paraneoplastic neuropathies are well recognized as a remote effect of cancer, and subacute sensory neuronopathy is a recognized syndrome. Demyelinating neuropathies are relatively rare. Distal acquired demyelinating symmetric (DADS) neuropathy associated with lymphoproliferative disease has been previously reported. We present the association of DADS neuropathy with solid tumor. Methods: We report the clinical presentation, electrophysiology and progress of DADS neuropathy in a patient later found to have colorectal adenocarcinoma. Results: A patient presented with subacute onset of symmetric distal sensory and motor symptoms. Electrophysiology was typical of DADS neuropathy. Anti‐MAG antibodies were initially positive at low‐titer, and indirect immunofluorescence analysis for anti‐nuclear antibodies revealed autoantibodies to centromere nuclear protein‐F (CENP‐F). There was clinical and electrophysiologic resolution following tumor resection. Conclusions: This case describes the presentation of DADS neuropathy as a paraneoplastic syndrome in a patient later found to have colorectal adenocarcinoma.
- 24 April 2015
- Published by Wiley in Muscle & Nerve
- Vol. 51 (6) , 928-931
Distal acquired demyelinating symmetric (DADS) neuropathy associated with colorectal adenocarcinoma
Introduction: Paraneoplastic neuropathies are well recognized as a remote effect of cancer, and subacute sensory neuronopathy is a recognized syndrome. Demyelinating neuropathies are relatively rare. Distal acquired demyelinating symmetric (DADS) neuropathy associated with lymphoproliferative disease has been previously reported. We present the association of DADS neuropathy with solid tumor. Methods: We report the clinical presentation, electrophysiology and progress of DADS neuropathy in a patient later found to have colorectal adenocarcinoma. Results: A patient presented with subacute onset of symmetric distal sensory and motor symptoms. Electrophysiology was typical of DADS neuropathy. Anti‐MAG antibodies were initially positive at low‐titer, and indirect immunofluorescence analysis for anti‐nuclear antibodies revealed autoantibodies to centromere nuclear protein‐F (CENP‐F). There was clinical and electrophysiologic resolution following tumor resection. Conclusions: This case describes the presentation of DADS neuropathy as a paraneoplastic syndrome in a patient later found to have colorectal adenocarcinoma.